drugset / Trial / NCT02040636

Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis

NCT02040636

Phase 2 Completed 277 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

Primary objective: * To determine the safety and immunogenicity of tetanus and diphtheria toxoids adsorbed combined with component pertussis and inactivated poliomyelitis vaccine grown on vero cells (TdcP-IPV) compared to tetanus and diphtheria toxoids adsorbed combined with component pertussis and inactivated poliomyelitis vaccine grown on vero cells (TdcP-IPV) and Hepatitis B vaccine administered concurrently in adolescents 11-14 years of age. Secondary objective: * To determine whether concurrent administration of TdcP-IPV and Hepatitis B vaccines at 11-14 years of age results in detectable immunologic interactions between components of the two vaccines.

Timeline

Start
1999-01
Primary completion
2000-05
Completion
2000-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Hepatitis B vaccine Vaccine 0.5 ml Intramuscular
Subject Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV Vaccine 0.5 ml Intramuscular